TY - JOUR
T1 - Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation
AU - for the
AU - Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Atsuta, Yoshiko
AU - Hirakawa, Akihiro
AU - Nakasone, Hideki
AU - Kurosawa, Saiko
AU - Oshima, Kumi
AU - Sakai, Rika
AU - Ohashi, Kazuteru
AU - Takahashi, Satoshi
AU - Mori, Takehiko
AU - Ozawa, Yukiyasu
AU - Fukuda, Takahiro
AU - Kanamori, Heiwa
AU - Morishima, Yasuo
AU - Kato, Koji
AU - Yabe, Hiromasa
AU - Sakamaki, Hisashi
AU - Taniguchi, Shuichi
AU - Yamashita, Takuya
N1 - Funding Information:
The authors are grateful for the assistance and cooperation of the staff members of the collaborating institutes of the cord blood banks in Japan, the Japan Marrow Donor Program, the Japan Society for Hematopoietic Cell Transplantation, and the members of the Late Effects and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation, especially Dr. Minako Iida for her helpful comments. The authors are also grateful for the data management support of the Japanese Data Center for Hematopoietic Cell Transplantation. This work was supported in part by a Research Grant for Allergic Disease and Immunology ( 26300301-108 ) from the Japanese Ministry of Health, Labor, and Welfare, and by Grants-in-Aid for Scientific Research for Young Scientists B ( 23791077 ) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.
Publisher Copyright:
© 2016 American Society for Blood and Marrow Transplantation
PY - 2016/9/1
Y1 - 2016/9/1
N2 - We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.
AB - We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.
KW - Causes of death
KW - Late effects
KW - Late mortality
UR - http://www.scopus.com/inward/record.url?scp=84979623023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979623023&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.05.019
DO - 10.1016/j.bbmt.2016.05.019
M3 - Article
C2 - 27246369
AN - SCOPUS:84979623023
VL - 22
SP - 1702
EP - 1709
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 9
ER -